Digest Network Come funziona
Network
/
Società
Ka
Non verificato

Kashiv Biosciences, LLC

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

12 comunicati stampa

Guarda tutti i comunicati
24/09/2025
Mercato del lavoro
Industria
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Kashiv BioSciences and JAMP Pharma Corporation Announce the Launch of PEXEGRA® and FILRA® Biosimilars in Canada
Fonte
Kashiv Biosciences, LLC
Emittente
Business Wire
1.00
0
11/09/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Mercato del lavoro
Industria
Kashiv BioSciences and CRISTÁLIA Enter into Licensing and Supply Agreement for Omalizumab Biosimilar (ADL-018) in Latin America
Fonte
Kashiv Biosciences, LLC
Emittente
Business Wire
1.00
0
05/08/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Kashiv BioSciences and MS Pharma Enter into MENA License and Supply Agreement for ADL-018, Biosimilar Candidate to XOLAIR® (bOmalizumab)
Fonte
Kashiv Biosciences, LLC
Emittente
Business Wire
1.00
0
25/06/2025
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Industria
Kashiv BioSciences Announces Positive Topline Results from Confirmatory Efficacy Study of ADL-018, Biosimilar Candidate to XOLAIR® (omalizumab)
Fonte
Kashiv Biosciences, LLC
Emittente
Business Wire
1.00
0
07/04/2025
Mercato del lavoro
Salute
Scienza
Farmaceutica
Biotecnologia
Kashiv BioSciences Secures $150 Million Debt Financing from GoldenTree Asset Management
Fonte
Kashiv Biosciences, LLC
Emittente
Business Wire
1.00
0
26/03/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
UK Medicines and Healthcare Products Regulatory Agency has Validated and Accepted the Marketing Authorization Application for ADL-018, a Proposed Biosimilar of Xolair® (omalizumab)
Fonte
Kashiv Biosciences, LLC
Emittente
Business Wire
1.00
0
25/02/2025
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Industria
Kashiv BioSciences, LLC Obtains Marketing Authorization for Pegfilgrastim Injection from Health Canada
Fonte
Kashiv Biosciences, LLC
Emittente
Business Wire
1.00
0
28/01/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Industria
Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002
Fonte
Kashiv Biosciences, LLC
Emittente
Business Wire
1.00
0
10/12/2024
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Kashiv Biosciences Expands Leadership Team with New Chief Financial Officer and Chief Legal Officer
Fonte
Kashiv Biosciences, LLC
Emittente
Business Wire
1.00
0
01/11/2024
Kashiv BioSciences Appoints Dr. Sandeep Nilkanth Athalye as Global CEO
Fonte
Kashiv Biosciences, LLC
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0